IRIS
CORTELLINI, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.071
EU - Europa 1.903
AS - Asia 1.590
SA - Sud America 311
Continente sconosciuto - Info sul continente non disponibili 104
AF - Africa 33
OC - Oceania 3
Totale 8.015
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.956
SG - Singapore 815
RU - Federazione Russa 499
IE - Irlanda 417
IT - Italia 344
BR - Brasile 267
CN - Cina 255
VN - Vietnam 197
DE - Germania 185
HK - Hong Kong 153
UA - Ucraina 88
FI - Finlandia 71
CA - Canada 66
GB - Regno Unito 56
SE - Svezia 50
CZ - Repubblica Ceca 42
NL - Olanda 34
PL - Polonia 29
JP - Giappone 28
TR - Turchia 25
MX - Messico 24
IN - India 23
FR - Francia 22
BD - Bangladesh 21
BE - Belgio 16
IQ - Iraq 16
ZA - Sudafrica 15
ES - Italia 13
AR - Argentina 11
EC - Ecuador 9
ID - Indonesia 9
HN - Honduras 8
CO - Colombia 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
JM - Giamaica 5
LT - Lituania 5
MY - Malesia 5
PH - Filippine 5
RO - Romania 5
VE - Venezuela 5
EE - Estonia 4
EG - Egitto 4
IL - Israele 4
JO - Giordania 4
KE - Kenya 4
MA - Marocco 4
UZ - Uzbekistan 4
AL - Albania 3
AT - Austria 3
AZ - Azerbaigian 3
CL - Cile 3
EU - Europa 3
PT - Portogallo 3
RS - Serbia 3
BG - Bulgaria 2
CH - Svizzera 2
CR - Costa Rica 2
GP - Guadalupe 2
GT - Guatemala 2
KH - Cambogia 2
KR - Corea 2
NZ - Nuova Zelanda 2
PE - Perù 2
PK - Pakistan 2
SA - Arabia Saudita 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AU - Australia 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GH - Ghana 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
KG - Kirghizistan 1
LU - Lussemburgo 1
MC - Monaco 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NP - Nepal 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TW - Taiwan 1
UY - Uruguay 1
Totale 7.914
Salva come PNG Salva come JPEG
Città #
Dallas 521
San Jose 452
Chandler 430
Singapore 421
Dublin 417
Ashburn 392
Jacksonville 307
Santa Clara 152
Council Bluffs 150
Hong Kong 150
Boardman 123
The Dalles 109
New York 105
Munich 77
Ho Chi Minh City 72
Beijing 66
Ann Arbor 61
Los Angeles 59
Lawrence 58
Princeton 58
Milan 54
Helsinki 47
Moscow 47
Wilmington 43
Brno 42
Amsterdam 33
Hanoi 33
São Paulo 28
Tokyo 28
Columbus 26
Rome 26
Warsaw 26
Bremen 21
Chicago 20
Montreal 20
Dong Ket 18
Brooklyn 17
Dearborn 17
Assago 16
Atlanta 16
Brussels 16
Frankfurt am Main 16
San Francisco 16
Stockholm 16
Denver 15
Phoenix 15
Falkenstein 14
Miano 14
Johannesburg 13
L'aquila 13
Naples 13
Orem 13
London 12
Turku 12
Brasília 11
Seattle 11
Izmir 10
Lappeenranta 10
Nanjing 10
Belo Horizonte 9
Da Nang 9
Chennai 8
Genoa 8
Mexico City 8
Rio de Janeiro 8
Toronto 8
Boston 7
Cagliari 7
Guayaquil 7
Lauterbourg 7
North Bergen 7
Poplar 7
Guangzhou 6
Haiphong 6
Houston 6
Hải Dương 6
L’Aquila 6
Nanchang 6
Pune 6
Shanghai 6
Ankara 5
Berlin 5
Catania 5
Florence 5
Hefei 5
Jakarta 5
Jinan 5
Manchester 5
New Delhi 5
Norwalk 5
Orlando 5
Palermo 5
San Mateo 5
Tianjin 5
Turin 5
Washington 5
Woodbridge 5
Amman 4
Asunción 4
Baghdad 4
Totale 5.253
Salva come PNG Salva come JPEG
Nome #
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 198
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 180
"Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer 167
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. 165
Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases 165
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 162
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 160
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 158
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 157
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 156
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 154
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 153
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice 151
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 151
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 150
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 150
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 150
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 146
Evaluation of prognostic factors for survival in transverse colon cancer 145
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome 141
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 141
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 139
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 137
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 134
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 134
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 134
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 132
A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients 132
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 131
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 130
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 128
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 128
Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen 127
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 125
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 125
Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study 125
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy 123
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 122
Cancer care after natural disaster: Different countries, similar problems 122
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 121
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 120
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 120
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 119
Rare bone toxicity associated with vismodegib 119
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 118
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 118
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 117
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 115
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 114
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 113
Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience 112
Studio sul ruolo della storia familiare di neoplasie come fattore predittivo surrogato per l'immunoterapia con inibitori dei checkpoint immunitari PD-1/PD-L1 111
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 111
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 99
Family history of cancer and DNA damage response genes: Two sides of the same coin? 99
Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report 94
"palliative" or "supportive": Is It Just a Matter of Word? 92
Practical Advices About How To Handle Disease Progression During Osimertinib In EGFR-Mutant NSCLC Patients: Is It The Same Old Story? A Mini Review 86
Prognostic relevance of Hormonal Receptor positive Status in HER2-positive Metastatic Breast Cancer Patients: Retrospective Analysis in Real Life 74
Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practice 73
First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen 73
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 69
Totale 8.015
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.577
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.577
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022188 0 0 0 8 11 4 3 19 23 2 23 95
2022/20231.193 65 95 9 148 88 114 2 89 516 6 43 18
2023/2024389 38 7 17 20 29 110 3 49 0 17 19 80
2024/20251.515 46 28 119 101 145 110 221 100 369 50 138 88
2025/20263.141 157 300 393 374 349 213 425 107 262 419 126 16
2026/2027789 79 60 189 461 0 0 0 0 0 0 0 0
Totale 8.015